News

Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
Company announcement - No. 15 / 2025 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Body weight reductions of a mean ...
Which is more effective for weight loss, GLP-1 drugs or surgery? new study has answer
GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...
The American Journal of Managed Care2h
GLP-1 Receptor Agonists Could Reduce Risk of Glaucoma in Type 2 Diabetes
Patients with type 2 diabetes had a lower risk of glaucoma when they used glucagon-like peptide 1 (GLP-1) receptor agonists across multiple studies.
Gastroenterology Advisor2h
GLP-1 RAs May Not Increase Acute Pancreatitis Risk in Type 2 Diabetes
Individuals with type 2 diabetes who receive treatment with GLP-1 RAs do not have an increased risk for acute pancreatitis.
Eolo Pharma Publishes First-in-Human Study in Nature Metabolism on Novel Obesity Drug Activating Energy-Burning Pathway
New data show clinical safety and early efficacy of SANA, a first-in-class compound that targets creatine-dependent thermogenesis MONTEVIDEO, Uruguay, June 18, 2025 (GLOBE NEWSWIRE) -- Eolo Pharma, a ...
Endocrinology Advisor15h
Could GLP-1 RAs Have Clinical Utility in Managing CV, Limb Outcomes in PAD?
In patients with moderate peripheral artery disease, use of GLP-1 RAs increases the likelihood of more favorable cardiovascular and major limb outcomes.